会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Erythromycin derivatives
    • 红霉素衍生物
    • US5658888A
    • 1997-08-19
    • US318814
    • 1994-10-19
    • Hiroshi KogaTsutomu SatoHisanori Takanashi
    • Hiroshi KogaTsutomu SatoHisanori Takanashi
    • C07D407/00C07H17/08A61K31/00A61K31/70A61K31/7042A61K31/7048A61P1/00A61P1/12A61P43/00C07M17/08
    • C07H17/08
    • Compounds represented by the general formula: ##STR1## wherein R.sub.1 is a hydrogen atom or an acyl group; R.sub.2 and R.sub.3 may be the same or different, and each represents a hydrogen atom, hydroxyl group, acyloxy group or amino group, or, in combination, they represent .dbd.O or .dbd.NOR.sub.10, where R.sub.10 represents a hydrogen atom or lower alkyl group;R.sub.4 represents a hydrogen atom or lower alkyl group; andY represents --NR.sub.5 R.sub.6 or --N.sup.+ R.sub.7 R.sub.8 R.sub.9 X.sup.-, where R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 may be the same or different, and each represents a hydrogen atom or an unsubstituted or substituted lower alkyl group, lower alkenyl group, lower alkinyl group, cycloalkyl group or 3-7-membered heterocyclic group comprising an oxygen atom, nitrogen atom or sulphur atom as an heteroatom, and X represents an anion, where R.sub.5 and R.sub.6, or R.sub.7 and R.sub.8 may form an azacycloalkyl group together with the neighboring nitrogen atom, respectively, and salts thereof.These compounds and their salts are subject to a remarkably lower degree of decomposition by gastric acid than are the publicly known erythromycin derivatives of the prior art, and have an excellent enterolinesis stimulating action.
    • PCT No.PCT / JP93 / 00702 Sec。 371日期:1994年10月19日 102(e)日期1994年10月19日PCT提交1993年5月26日PCT公布。 出版物WO93 / 24509 日期1993年12月9日化合物由通式表示的化合物:酰基; R2和R3可以相同或不同,各自表示氢原子,羟基,酰氧基或氨基,或者组合表示= O或= NOR10,其中R10表示氢原子或低级烷基; R4代表氢原子或低级烷基; 并且Y表示-NR5R6或-N + R7R8R9X-,其中R5,R6,R7,R8和R9可以相同或不同,并且各自表示氢原子或未取代或取代的低级烷基,低级烯基,低级炔基 基团,环烷基或包含氧原子,氮原子或硫原子作为杂原子的3-7元杂环基,X表示阴离子,其中R 5和R 6或R 7和R 8可以与相邻的基团一起形成氮杂环烷基 氮原子及其盐。 与现有技术中公知的红霉素衍生物相比,这些化合物及其盐受胃酸分解程度明显降低,具有优异的肠溶激素作用。
    • 7. 发明授权
    • Toner cartridge
    • 墨粉盒
    • US07957680B2
    • 2011-06-07
    • US11749280
    • 2007-05-16
    • Tsutomu Sato
    • Tsutomu Sato
    • G03G15/08B01F7/02
    • G03G15/0875G03G15/0877G03G2215/0802
    • A toner cartridge inserted in an image forming apparatus and supplying toner to the image forming apparatus comprises a container which contains the toner and provided with a discharging opening for discharging the contained toner, the container having a shape with a predetermined curvature at a bottom part, a conveying member which conveys the toner in the container to the discharging opening, an agitating member which rotates centering on a rotational axis in the container, and agitates the toner contained in the container and a sheet member provided in the agitating member such that a front edge part abuts the bottom part of the container, the sheet member having the front edge part which is formed with a part having substantially the same curvature as the bottom part of the container.
    • 插入图像形成装置中并且向成像装置供应调色剂的调色剂盒包括容纳调色剂并且设置有用于排出所容纳的调色剂的排出口的容器,所述容器在底部具有预定曲率的形状, 输送构件,其将容器中的调色剂输送到排出口,搅拌构件,其以容器中的旋转轴线为中心旋转,并且搅拌容纳在容器中的调色剂和设置在搅拌构件中的片材构件, 边缘部分邻接容器的底部,片状构件具有形成有与容器的底部基本相同曲率的部分的前边缘部分。
    • 9. 发明授权
    • Spiroketal derivatives and use thereof as diabetic medicine
    • 螺缩酮衍生物及其作为糖尿病药物的用途
    • US07767651B2
    • 2010-08-03
    • US11815074
    • 2006-01-27
    • Takamitsu KobayashiTsutomu SatoMasahiro Nishimoto
    • Takamitsu KobayashiTsutomu SatoMasahiro Nishimoto
    • A01N43/04C07H1/00C07H3/00C08B37/00
    • C07D311/96C07D491/153C07D493/10C07H19/01
    • The present invention provides a compound of Formula (I): wherein R1, R2, R3 and R4 are each independently selected from a hydrogen atom, an optionally substituted C1-C6 alkyl group, an optionally substituted C7-C14 aralkyl group and —C(═O)Rx; Rx represents an optionally substituted C1-C6 alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted C1-C6 alkoxy group or —NReRf; Ar1 represents an optionally substituted aromatic carbocyclic ring or an optionally mono-substituted aromatic heterocyclic ring; Q represents —(CH2)m-(L)p- or -(L)p-(CH2)m—; m represents an integer selected from 0 to 2, n represents an integer selected from 1 and 2, and p represents an integer selected from 0 and 1; L represents —O—, —S— or —NR5—; and A represents an optionally substituted aryl group or an optionally substituted heteroaryl group, a prodrug thereof and a pharmaceutically acceptable salt thereof, as well as a pharmaceutical preparation or pharmaceutical composition comprising such a compound.
    • 本发明提供式(I)的化合物:其中R 1,R 2,R 3和R 4各自独立地选自氢原子,任选取代的C 1 -C 6烷基,任选取代的C 7 -C 14芳烷基和-C( ΟO)Rx; Rx表示任选取代的C 1 -C 6烷基,任选取代的芳基,任选取代的杂芳基,任选取代的C 1 -C 6烷氧基或-NRrf; Ar 1表示任选取代的芳族碳环或任选单取代的芳族杂环; Q表示 - (CH 2)m - (L)p-或 - (L)p-(CH 2)m - ; m表示选自0至2的整数,n表示选自1和2的整数,p表示选自0和1的整数; L表示-O - , - S-或-NR5-; A表示任选取代的芳基或任选取代的杂芳基,其前药及其药学上可接受的盐,以及包含这种化合物的药物制剂或药物组合物。